Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a major global health challenge. Current management relies primarily on comprehensive lifestyle interventions, including dietary modification, regular physical activity, weight loss, management of metabolic risk factors, and emerging pharmacotherapies. The gluten-free diet (GFD) was originally developed for the treatment of celiac disease and has attracted attention in recent years for its potential metabolic benefits. Existing studies suggest that gluten- or wheat-targeted dietary interventions may affect MASLD-related pathways, including the gut microbiota, inflammation, insulin sensitivity, and liver fat accumulation. In patients with concurrent celiac disease and MASLD, a GFD is indicated for celiac disease, but its hepatic and metabolic effects are variable. However, clinical and mechanistic evidence for its potential effects in patients with non-celiac MASLD is limited and heterogeneous, relying largely on indirect evidence from animal models; furthermore, long-term, unsupervised adherence to a GFD may adversely affect metabolic health. This narrative review critically evaluates the therapeutic boundaries of gluten-targeted interventions, compares the gluten-free diet with established dietary patterns, and outlines challenges related to nutritional adequacy, cost, and adherence. Future research should focus on high-quality randomized controlled trials to identify the specific benefits and risks of gluten removal in patients with non-celiac MASLD and to inform more precise dietary guidance.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: